09/10/2024 | Press release | Distributed by Public on 09/10/2024 01:12

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second Line Non Small Cell Lung Cancer

Please select the service you want to use:

• Newsvine
• Digg
• Delicious
• StumbleUpon
• Technorati
• Buzz
• Favorites
• Google Reader

 Back

 Download the original document